Adimmune Corp (4142) Fair Value & Analysis
Healthcare · TW · Market cap 7.2B TWD (≈ $226M) · ISIN TW0004142005
What is Adimmune Corp really worth?
Below-average quality, and trading another 80% above our fair value of 9.74 TWD.
As of Aug 13, 2026, the fair value of Adimmune Corp is 9.74 TWD per share against a price of 17.55 TWD, so the fair value sits 45% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 23 days ago
Fair value updated Aug 13, 2026, revised from 11.12 TWD to 9.74 TWD (−12.4%) since Jul 21, 2026. Share price +2.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (15.45 TWD). The favourable scenario is already priced in.
- Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (4.68 TWD to 15.45 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 16.00 TWD – 62.72 TWD · fair‑value band 4.68 TWD – 15.45 TWD · the 17.55 TWD price screens above the 9.74 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Adimmune Corp (4142) currently trades at 17.55 TWD, while our model-based Fair Value estimate is 9.74 TWD, implying the stock looks roughly 80.2% overvalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bull case: the Asset-Based group reads highest at a median of 7.86 TWD per share, and 0 of the 3 models we run sit above the 17.55 TWD price. Bear case: the Dividend Discount group reads lowest at 7.22 TWD, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Adimmune Corp generated revenue of 1.4B TWD at a net margin of −14.3%. Revenue grew 14.2% year over year. It earns a return on equity of −5.4%. Net debt stands at 644M TWD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 4.68 TWD (bear case) to 15.45 TWD (bull case); at 17.55 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −45%, 4142 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 3 models by family
Widest divergence: Asset-Based (7.86 TWD) versus Dividend Discount (7.22 TWD). Highest evidence: Gordon GGM (67).
Notify me when 4142 reaches fair value
Put 4142 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally.
Full company description
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Adimmune Corp reported revenue of 1.4B TWD in FY2025 versus 1.6B TWD in FY2021, a compound −3.9%/yr. Reported net income was −240M TWD in FY2025.
4142 screens 80% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Adimmune Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Adimmune Corp (4142) overvalued or undervalued?
What is the fair value of 4142?
What is the quality score of 4142?
What is the price target for Adimmune Corp (4142)?
What is the Adimmune Corp stock forecast for 2026?
What is the revenue of Adimmune Corp (4142)?
What is the net profit margin of 4142?
Does Adimmune Corp pay a dividend?
Watch Adimmune Corp in the live analysis
One click puts Adimmune Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.